Nos Publications

Développement de l’alphathérapie dans le traitement des tumeurs neuroendocrines différenciées.
Lugat A.
Journée scientifique TransForMed4Students, Nantes (Loire Atlantique), France, 6 juillet 2021

64Cu-ATSM as a therapeutic agent in solid tumor? preliminary results of a whole body human dosimetry study OP-0360.
Varmenot N, Colombié M, Rousseau C, Haddad F, Ferrer L
EANM’21 34th Annual congress of the European Association of Nuclear Medicine, édition virtuelle, 20-23 octobre 2021

Preclinical study of Targeted Alpha Therapy using 211At-labeled phenylalaline derivative in a syngeneic Multiple Myeloma model OP-0106.
Gaschet J, Echeynne R, Chouin N, Gazzola S, Guérard F, Gouard S, Marionnaud-Lambot S, Maubert AL, Alliot C, Hofgaard PO, Bogen B, Yan E, Haddad F, Kraeber-Bodéré F, Wheatcroft M, Gestin JF, Chérel M
EANM’21 34th Annual congress of the European Association of Nuclear Medicine, édition virtuelle, 20-23 octobre 2021

Preliminary evaluation of 64Cu-ATSM as a tracer of predictive assessment of neoadjuvant treatment response in locally advanced rectal cancer OP-0062.
Colombié M, Ferrer L , Lacombe M, Fleury V, le Thiec M, Morel A, Maugerat B, Rusu D, Varmenot N, Tremolieres P, Allam N, Rio E, Guimas V, Masson I, Senellart H, Hiret S, Salaun PY, Campion L, Vidal A, Haddad F, Rauscher A, Kraeber-Bodéré F, Bourgeois M, Rousseau C
EANM’21 34th Annual congress of the European Association of Nuclear Medicine, édition virtuelle, 20-23 octobre 2021

Evaluation théranostique d’un anticorps radiomarqué au cuivre-64 dans un modèle murin de myélome multiple.
Métivier C, Le Saëc P, Marionneau-Lambot S, Chauvet C, Hofgaard PO, Bogen B, Gaschet J, Tripier R, Haddad F, Chérel M, Chouin N, Faivre-Chauvet A, Rbah-Vidal L
15èmes Journées annuelles du Cancéropôle Grand-Ouest, Angers, France, 1-2 juillet 2021

Theranostic evaluation of a copper-64 radiolabelled antibody in a mouse model of multiple myeloma
Métivier C, Le Saëc P, Marionneau-Lambot S, Chauvet C, Hofgaard PO, Bogen B, Gaschet J, Tripier R, Haddad F, Chérel M, Chouin N, Faivre-Chauvet A, Rbah-Vidal L
14th Workshop Adaptation of the tumour and its ecosystem to radiotherapies, Le Bono, France, 22-25 septembre 2021

In vivo theranostic evaluation of a 64Cu-radiolabelled antibody in a murine model of multiple myeloma
Métivier C, Remaud-Le Saëc P, Marionneau-Lambot S, Davodeau F, Chauvet C, Saï-Maurel C, Hofgaard PO, Bogen B, Tripier R, Haddad F, Gaschet J, Chérel M, Chouin N, Faivre-Chauvet A, Rbah-Vidal L
14th Workshop Adaptation of the tumour and its ecosystem to radiotherapies, Le Bono, France, 22-25 septembre 2021

Interest of whole-body immuno-SPECT-CT for canine diffuse large B-cell lymphoma (DLBCL) staging before radioimmunotherapy (RIT) using an anti-CD22 monoclonal antibody
Etienne F, Nguyen F, Becavin S, Bodet-Milin C, Bourgeois M, Vidal A, Abadie J, Bouhsina N, Davodeau F, Ibisch C, Chouin N
European Society of Veterinary Oncology (ESVONC) Conference, virtual edition, 28-29 mai 2021

Promising Clinical Performance of Pretargeted Immuno-PET with Anti-CEA Bispecific Antibody and Gallium-68-Labelled IMP-288 Peptide for Imaging Colorectal Cancer Metastases: A Pilot Study, Touchefeu, Y.; Bailly, C.; Frampas, E.; Eugène, T.; Rousseau, C.; Bourgeois, M.; Bossard, C.; Faivre-Chauvet, A.; Rauscher, A.; Masson, D.; David, A.; Cerato, E.; Carlier, T.; Sharkey, R. M.; Goldenberg, D. M.; Barbet, J.; Kraeber-Bodere, F.; Bodet-Milin, C., Eur J Nucl Med Mol Imaging 2021, 48 (3), 874–882. doi:10.1007/s00259-020-04989-3

Anti-CEA Pretargeted Immuno-PET Shows Higher Sensitivity Than DOPA PET/CT in Detecting Relapsing Metastatic Medullary Thyroid Carcinoma: Post Hoc Analysis of the IPET-MTC Study, Bodet-Milin, C.; Faivre-Chauvet, A.; Carlier, T.; Ansquer, C.; Rauscher, A.; Frampas, E.; Toulgoat, F.; Masson, D.; Bourgeois, M.; Cerato, E.; Rohmer, V.; Couturier, O.; Drui, D.; Goldenberg, D. M.; Sharkey, R. M.; Barbet, J.; Kraeber-Bodere, F., J Nucl Med 2021, 62 (9), 1221–1227. doi:10.2967/jnumed.120.252791